Sandoz Ag

Marijan Stefinovic

Ulrich Griesser

Erwin Schreiner

Christoph Langes

Johannes Raneburger

Thomas Gelbrich

Hayley Reece

Ludwig Englmeier

Asha Sunkara

Clemens Haefele

Dennis Dimo Enkelmann

The present invention relates to co-crystals comprising levothyroxine and a dicarboxylic acid, preferably L-tartaric acid or oxalic acid, and processes for the preparation thereof. Furthermore, the invention relates to a pharmaceutical composition comprising a co-crystal of the present invention, preferably the co-crystal comprising levothyroxine and L-tartaric acid or oxalic acid, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of hypothyroidism.

Co-crystals comprising levothyroxine and a dicarboxylic acid

The present invention relates to crystalline valbenazine ditosylate, in particular to a crystalline hydrate of valbenazine ditosylate and a crystalline anhydrate of valbenazine ditosylate, and to methods for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising the crystalline hydrate or the crystalline anhydrate, preferably in an effective and/or predetermined amount and to the use of said pharmaceutical composition as a medicament, in particular for the treatment of hyperkinetic movement disorders such as tardive dyskinesia. 

Crystalline forms of valbenazine salts

The present invention relates to crystalline forms of cabozantinib succinate (Form A) and cabozantinib acetate (Form A-1) and to pharmaceutical compositions comprising said crystalline forms and their use as anti-cancer medicaments.

Cabozantinib salts and their use as anti-cancer agents

The present invention relates to crystalline forms of cabozantinib phosphoric acid salt and cabozantinib hydrochloric acid salt and to a method for their preparation. Furthermore, the invention relates to pharmaceutical compositions comprising said crystalline forms and their use as anti-cancer medicaments. Cabozantinib, i.e. N-{4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl}-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide is represented by the chemical structure: Formula.

Crystalline forms of cabozantinib phosphate and cabozantinib hydrochloride

The present invention relates to an oral solid dosage form, in particular a tablet, comprising macitentan free base polymorphic form I.

Pharmaceutical composition containing crystalline macitentan

The present disclosure relates to polymorphic forms of the hydrochloride salt of ponatinib ('compound 1') and to processes for the preparation of these polymorphic forms. The present disclosure also generally relates to a pharmaceutical composition comprising the forms, as well of methods of using the form(s) in the treatment of disorders associated with pathological cellular proliferation, such as neoplasms, and cancer.

Crystalline forms of ponatinib hydrochloride

The invention relates to a new solvate, Vilazodone hydrochloride monoethanol monohydrate solvate, and to a process for the preparation of polymorphic form III of Vilazodone hydrochloride via the Vilazodone hydrochloride monoethanol monohydrate solvate.

Growing community of inventors

Kundl, Austria

Marijan Stefinovic